Open AccessCardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
Author(s) -
Chang ChiaHsuin,
Chuang LeeMing
Publication year - 2018
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12776
Subject(s) - medicine , insulin glargine , insulin , type 2 diabetes , diabetes mellitus , myocardial infarction , insulin degludec , heart failure , stroke (engine) , cardiology , endocrinology , mechanical engineering , engineering
In 2008, the U.S. Food and Drug Administration requested that all new type 2 anti-diabetic drugs, including long-acting insulin analogues, need to be rigorously examined to preclude undesirable cardiovascular risks. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is the first trial to provide conclusive evidence of the cardiovascular safety of insulin glargine. A total of 12,537 people with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes were randomized to receive insulin glargine or standard care. This article is protected by copyright. All rights reserved.